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Association Between Neutralizing Antibody Titers against Parechovirus A3 in Maternal 
and Cord Blood Pairs and Perinatal Factors 
（パレコウイルス A3型に対する母体血、臍帯血の中和抗体価と周産期因子との関連） 
 
ABSTRACT 
Background. Parechovirus A3(PeV-A3) is a pathogen that causes severe infectious diseases 
such as sepsis and meningoencephalitis in neonates and young infants. This study aimed to 
measure neutralizing antibody titers (NAT) against PeV-A3 in paired maternal blood and cord 
blood samples and to clarify the serum epidemiology of PeV-A3 as well as the association 
among NAT and perinatal factors. 
Methods. NAT against PeV-A3 were measured in 1033 mothers (maternal blood and cord 
blood pairs; total 2066 samples) who delivered in Fukushima Prefecture between December 
2013 and June 2014. RD-18S cells were used to measure NAT against PeV-A3. The 
association among NAT against PeV-A3 in maternal blood and cord blood and perinatal 
factors was determined using multivariate logistic regression analysis. 
Results. The median gestational age of the infants was 39 weeks 4 days (interquartile range: 
38 weeks 4 days–40 weeks 3 days). NAT against PeV-A3 in maternal blood and cord blood 
were almost the same. The rate of low titer group (NAT ≤ 1:16) was approximately 70% and 
that of high titer group tended to increase with gestational age. The rate of high titer group 
and geometric mean titer decreased with increased maternal age. 
Conclusions. Neonates born to shorter gestational age and older mothers have low NAT 
against PeV-A3 in cord blood. Thus, more attention should be paid to the onset of severe 
PeV-A3 disease in such neonates and young infants. 
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Abbreviation:  
PeV-A3: parechovirus A3 
NAT: Neutralizing Antibody Titers 
JECS: the Japan Environment and Children’s Study 
GA: gestational age 
MEM: Eagle’s minimum essential medium 
FBS: fetal bovine serum 
MM: maintenance medium 
CPE: cytopathic effect 
TCID50: the 50% tissue culture infective dose  
HTG: high titer group 
LTG: ligh titer group 
GMT: geometric mean titer 
IQR: interquartile range 
aOR: adjusted odds ratio 
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INTRODUCTION 
Parechoviruses (PeVs) are non-enveloped RNA viruses within the Parechovirus genus of the 
Picornaviridae family and mainly cause gastroenteritis and respiratory infections in children 
[1]. To date, 17 genotypes of PeVs have been identified; the most common genotypes isolated 
from patients in Japan are Parechovirus A1(PeV-A1), A3(PeV-A3), and A6 [2]. Ito et al. first 
reported PeV-A3 in Japan in 2004 [3]. PeV-A3 has recently attracted attention due to causing 
severe infectious diseases with sepsis and meningoencephalitis in neonates and young infants 
[4–9]. The onset of severe infectious disease is thought to be associated with a lack of or low 
levels of maternal antibody [10–12]. To date, there have been no reports on neutralizing 
antibody titers (NAT) against PeV-A3 in maternal blood and cord blood pairs. This study 
aimed to clarify the serum epidemiology of NAT against PeV-A3 and to determine the 
association among the NAT and perinatal factors in mothers and their neonates. Our results 
may help predict the onset of infection and prevent severe PeV-A3 disease in neonates and 
young infants. 
MATERIALS AND METHODS 
Participants 
This study was conducted by Fukushima Regional Center as an adjunct study of the Japan 
Environment and Children’s Study (JECS). Paired maternal blood and cord blood samples of 
1033 mothers (total 2066 samples) who delivered in Fukushima Prefecture between 
December 2013 and June 2014 were analyzed. Information about this study was provided on 
our web site and via newsletters mailed to all participants in the JECS. Mothers did not 
consent to participate in this study were excluded from the study (opt-out system). This study 
was approved by the Ministry of the Environment Government of Japan and the ethics 
committee of the Fukushima Medical University (number #2124). 
Perinatal background  
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The perinatal background was obtained from JECS dataset. Maternal background included 
maternal age, gestational age (GA), maternal smoking (defined as smoking when pregnancy 
had become apparent and/or during pregnancy), maternal obesity (defined as body mass 
index ≥ 25 kg/m2 prior to pregnancy), the number of deliveries, mode of delivery, and 
obstetric complications. Neonatal information included birth weight, sex, the number of 
siblings, Apgar score, umbilical arterial blood pH, and morbidity at 6 months (Subjects 
diagnosed with non-PeV-A3 infections such as respiratory syncytial virus, rotavirus, and 
adenovirus infections were excluded). In addition, serum IgG levels in the maternal blood 
and cord blood were measured by a commercial company (SRL, Inc. Tokyo, Japan) using 
enzyme-linked immunosorbent assay. 
Viruses and cells 
Virus Strains 
PeV-A3 1356-Yamagata-2008 strain was used for analysis and was cultured in RD-18S cells. 
These viruses were stored at −80°C until completion of the neutralization test. 
Cell Culture  
RD-18S cells were used for replicating PeV-A3 strain. Eagle’s minimum essential medium 
(MEM) (Thermo Fisher Scientific, Waltham, MA USA) comprising 10% heat-inactivated 
fetal bovine serum (FBS), glutamine (600 µg/mL), penicillin (100 U/mL), gentamicin (50 
μg/mL), and amphotericin B (1 μg/mL) was used as a growth medium for RD-18S cells, 
which were cultured at 37°C in 5% CO2 for 5 days. 
Virus Titration 
Virus was serially diluted using maintenance medium (MM), which was MEM with 5% FBS. 
The diluted virus solution was inoculated on RD-18S cells in a 96-well microplate and 
cultured for 5 days in MM. The cytopathic effect (CPE) was observed by microscope. The 
virus titer was determined according to the 50% tissue culture infective dose (TCID50).  
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Neutralization Test 
Serum samples were inactivated at 56°C for 30 min and serially mixed in two-fold dilutions 
from 1:4 to 1:1024 using MM. 200 TCID50/0.05 mL virus was added per well and incubated 
at 37°C in 5% CO2 for 2 h. Confluent monolayers of the RD-18S cells were prepared in a 
96-well microplate, and the incubated virus–serum mixture was added to each well. 
Subsequently, these plates were cultured at 34°C in 5% CO2 for 5 days. The CPE was 
assessed by microscope. NAT were determined as the reciprocal of the highest serum dilution 
that inhibited the CPE by 50%. The titer for preventing the onset of severe PeV-A3 disease 
was set at 1:32, as previously reported [11]. Serum samples were classified according to NAT 
into the high titer group (HTG) (NAT ≥ 1:32) or the low titer group (LTG) (NAT ≤ 1:16).  
Statistical analysis 
Statistical analysis was performed using Stata/SE 14 (Stata Corp. LLC, Texas, USA). The 
association between NAT against PeV-A3 in maternal blood and cord blood was examined 
using Kappa statistics. The rate of HTG was compared using the chi-square test and 
geometric mean titer (GMT) was compared using the Kruskal–Wallis test and Mann–Whitney 
test. Categorical variables and continuous variables between LTG and HTG were compared 
using the chi-square test and the Mann–Whitney test. The association among NAT against 
PeV-A3 and perinatal factors was evaluated by multivariate logistic regression analysis. P < 
0.05 was considered statistically significant. 
RESULTS 
Clinical Characteristics of mothers and neonates 
NAT were measured in 1033 maternal blood and cord blood pairs. The median maternal age 
was 30 years [interquartile range (IQR): 27–34 years)]; median GA was 39 weeks 4 days 
(IQR: 38 weeks 4 days–40 weeks 3 days); and median birth weight was 3064 g (IQR: 
2790–3305 g). In total, 612 mothers (59.2%) had previously given birth, and 175 mothers 
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(16.9%) delivered by cesarean section. (Table 1). 
NAT in maternal blood and cord blood  
The rate of HTG and GMT in maternal blood and cord blood were 27.3% and 9.1 and 28.7% 
and 8.3, respectively. There was no significant difference in the rate of HTG and GMT 
between the maternal blood and cord blood. The NAT was ≤1:16 in approximately 70% of 
mothers and neonates. In addition, NAT in maternal blood and cord blood samples were 
almost the same using the Kappa statistic (kappa coefficient 0.95, p < 0.01).  
NAT by maternal age and GA 
When the data were stratified by maternal age, the rate of HTG and GMT decreased with 
increased maternal age, these were significant in both maternal blood and cord blood. There 
was no difference in the rate of HTG and GMT between maternal blood and cord blood, 
which was excepted for the groups of ≥35 years of age in GMT (Table 2.1). When the data 
were stratified by GA and analyzed with multiple comparisons, the rate of HTG in cord blood 
in the group of ≥40 weeks was higher than that in the group of 37–39 weeks. There was no 
difference in the rate of HTG and GMT between maternal blood and cord blood, which was 
excepted for the group of 37–39 weeks in GMT (Table 2.2). 
Differences in Perinatal Factors between LTG and HTG 
The number of maternal blood samples in the LTG and HTG were 751 (72.7%) and 282 
(27.3%), respectively. The median maternal age in the LTG and HTG was 31 years (IQR: 
28–35 years) and 28 years (IQR: 25–31 years), respectively. The median GA in the LTG and 
HTG was 39 weeks 4 days (IQR: 38 weeks 4 days–40 weeks 3 days) and 39 weeks 6 days 
(IQR: 39 weeks 0 days–40 weeks 3 days), respectively. Pregnancy-induced hypertension  
was observed in 4.0% and 1.1% of subjects in LTG and HTG, respectively. There were no 
significant differences between the LTG and HTG with serum IgG levels, maternal smoking, 
maternal obesity, sex, and the number of siblings.  
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The number of cord blood samples in the LTG and HTG were 737 (71.3%) and 296 (28.7%), 
respectively. The median maternal age in the LTG and HTG was 31 years (IQR: 28–35 years) 
and 28 years (IQR: 25–31, years), respectively. The median GA in the LTG and HTG was 39 
weeks 3 days (IQR: 38 weeks 4 days–40 weeks 2 days) and 39 weeks 6 days (IQR: 39 weeks 
0 days–40 weeks 4 days), respectively. The median serum IgG level in the LTG and HTG was 
1165 mg/dL (IQR: 1005–1365 mg/dL) and 1268 mg/dL (IQR: 1077–1440 mg/dL), 
respectively. There were no significant differences between the LTG and HTG with maternal 
smoking, maternal obesity, pregnancy-induced hypertension, sex, and the number of siblings 
(Table 3).  
Association between NAT and Perinatal Factors by Multivariate Logistic Regression 
Analysis 
Multivariate logistic regression analysis revealed significant differences between the LTG and 
HTG in maternal blood with maternal age [adjusted odds ratio (aOR): 0.89, 95% confidence 
interval (CI): 0.86–0.92], serum IgG levels (aOR: 1.00, 95% CI: 1.00–1.01) and number of 
siblings (aOR: 1.22, 95% CI: 1.02–1.45). There were significant differences between the LTG 
and HTG in cord blood with maternal age (aOR: 0.90, 95% CI: 0.87–0.93), GA (aOR: 1.16, 
95% CI: 1.01–1.33), and serum IgG levels (aOR: 1.00, 95% CI: 1.00–1.01) (Table 4). 
DISCUSSION 
To the best of our knowledge, this is the first study to evaluate NAT against PeV-A3 in 
maternal blood and cord blood pairs. This study revealed the serum epidemiology of NAT 
against PeV-A3 in neonates and the association among NAT and perinatal factors because 
many perinatal factors were simultaneously investigated with large sample size. In conclusion, 
the factors associated with NAT against PeV-A3 in cord blood are maternal age, GA, and 
serum IgG level. 
Severe enterovirus infections in neonates are associated with low NAT [12] and a lack of 
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maternal antibodies is a risk factor for severe infectious disease [13]. Maternal antibody plays 
an important role in preventing severe PeV-A3 disease [11]. To date, the prevalence of 
PeV-A3 antibody has been reported in Japan (Aichi and Niigata Prefectures), Finland, and the 
Netherlands [3,14,15], and the seroprevalence was found to be 74%, 61%, 13%, and 10%, 
respectively. In this study, the rates of HTG and GMT to PeV-A3 decreased with increased 
maternal age in both maternal blood and cord blood, which was consistent with previous 
studies. PeV-A1 has also been reported to cause gastroenteritis and respiratory infection in 
children; however, there are few reports of severe infectious disease in neonates and young 
infants [16, 17]. An epidemiological study in Finland revealed that 95% of neonates had 
neutralizing antibody against PeV-A1 [18]. Watanabe et al. reported the NAT against both 
PeV-A1 and PeV-A3. The rate of HTG against PeV-A1 peaked at 90% by 3 years of age and 
remained to be high with no decrease after 35 years of age. However, in the PeV-A3 began to 
decrease at 35 years of age [14]. Globally, PeV-A3 is epidemic every 2–3 years and PeV-A1 
is epidemic every year [19]; therefore, NAT against PeV-A3 may decrease because of reduced 
reinfection or boosting. In addition, because the viral protein region (the antigenic 
determinant of PeV-A3) is always changing, the latest strains of PeV-A3 cannot be 
neutralized by serum from older age [20]. These reasons were considered to be the decrease 
in NAT against PeV-A3 with age. 
Generally, the maternal antibody transfer is believed to begin at around the GA of 16 weeks 
and shows a linear increase; thereafter, the antibody levels in term infants are similar to or 
higher than those in mothers. Multivariate analysis showed a positive correlation between the 
serum IgG level and NAT and suggested that there is a certain amount of PeV-A3-antibody in 
the maternal antibody. In addition, there was also a positive correlation between NAT and GA 
in cord blood which suggested that transplacental transfer including PeV-A3-antibody from 
mother to the fetus increases as GA prolongs (Table 4). We hypothesized that NAT against 
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PeV-A3 would show significant differences between maternal blood and cord blood in 
premature infants. However, there were no differences between maternal blood and cord 
blood samples in NAT in premature infants (Table 2.2). The reason for no significant 
difference was believed to be that almost all premature infants (median: 36 weeks 0 day, IQR: 
33 weeks 4 days–36 weeks 5 days) were late-preterm infants; therefore, further research is 
required comprising cases with shorter GA. 
Some studies have found that PeV-A3 infection occurs predominantly in males [21–23], but 
there was no difference with sex between the HTG and LTG in this study.  
PeV-A3 tends to infect young children, and going to nursery school and kindergarten is 
believed to be risk factors for infection. Many children who developed severe PeV-A3 
disease had sick contacts within the family [24]. Recently, an asymptomatic PeV-A3-infected 
child reportedly transmitted the virus to family members [25], and the adults with low NAT 
are infected with PeV-A3 and they may also be the source of infection. In our study, the 
number of siblings was examined as neonatal information and there was association between 
them and NAT in maternal blood in multivariate analysis. Because mothers have an increased 
risk of reinfection in PeV-A3 from children with increase in the number of their children, 
NAT may therefore increase. 
The strengths of this study are the large sample size, the use of maternal and cord blood 
paired sample, and data on many perinatal variables. Low NAT in cord blood could be 
distinguished into impaired placental transmission or inadequate production of antibody in 
mother, owing to the use of paired samples.  
However, this study has some limitations. First, we could not track whether infants with low 
NAT in cord blood actually had PeV-A3 infection. Second, because the proportion of 
late-preterm infants in premature birth was high, it could not completely clarify the 
association between premature birth and NAT in cord blood. 
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We conclude that NAT against PeV-A3 in maternal blood and cord blood are almost the same 
in full-term infants. Infants born to shorter GA and older mothers may have low NAT against 
PeV-A3. Therefore, more attention should be paid to the onset of severe PeV-A3 diseases. 
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Table 1. Subject Characteristics (1033 mothers and neonates) 
Characteristic Number 
Maternal age (years), median (IQR) 30 (27–34) 
Gestational age (weeks-days), median (IQR) 39-4 (38-4–40-3) 
Multipara, n (%) 612 (59.2) 
Delivery type: cesarean section, n (%) 175 (16.9) 
Gestational diabetes mellitus, n (%) 13 (1.1) 
Pregnancy-induced hypertension, n (%) 33 (3.3) 
Maternal smoking, n (%) 193 (18.8) 
Premature birth, n (%) 43 (4.2) 
Birth weight (g), median (IQR) 3064 (2790–3305) 
Low birth weight infant, n (%) 80 (7.7) 
Male, n (%) 521 (50.4) 
Number of siblings in neonates, median (IQR) 1 (0–1) 
5-min Apgar score, median (IQR) 9 (9–9) 
Morbidity at 6 months of age, n (%) 236 (23.4) 
Abbreviations: IQR, interquartile range 
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Table 2.1. The Rate of High Titer Group and Geometric Mean Titer in Maternal Blood and Cord Blood by Maternal Age 
Maternal age 
 (n) 
< 25years 
 (125) 
25–29 years 
 (347) 
30–34 years  
(337) 
≥ 35years 
 (224) 
p value 
The rate of HTG, 
% (n) 
MB 44.0 (55) 34.0 (118) 22.6 (76) 14.7 (33) <0.01a 
CB 44.8 (56) 36.9 (128) 23.1 (78) 15.2 (34) <0.01a 
p value (MB/CB) 0.90a 0.43a 0.85a 0.90a ― 
GMT (95% CI) MB 15.0 (11.2–20.2) 11.7 (10.0–13.8) 7.9 (6.8–9.2) 5.8 (4.8–7.1) <0.01b 
CB 15.4 (11.2–21.2) 11.5 (9.6–13.8) 7.0 (5.9–8.3) 4.6 (3.7–5.7) <0.01b 
p value (MB/CB)  0.75c 0.70c 0.14c 0.03c ― 
Abbreviations: HTG, high titer group; MB, maternal blood; CB, cord blood; GMT, geometric mean titer; CI, confidence interval 
achi-square test, bKruskal–Wallis test, cMann–Whitney test   
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Table 2.2. The Rate of High Titer Group and Geometric Mean Titer in Maternal Blood and Cord Blood by Gestational Age 
 
Gestational age 
 (n) 
A 
< 37 weeks  
(43) 
B 
37–39 weeks 
 (574) 
C 
≥ 40 weeks 
(416) 
p value (multiple comparisons) 
A/B B/C A/C 
Maternal age (years), median (IQR) 32 (28–35) 30 (27–34) 30 (27–33) 0.21a  0.21a 0.04a 
The rate of HTG, 
% (n) 
MB 20.9 (9)  24.7 (142) 31.5 (131) 1.00b 0.07b 0.63b 
CB 23.3 (10)  24.7 (142) 34.6 (144) 1.00b <0.01b 0.55b 
p value (MB/CB) 0.80b 1.00b 0.34b  ― ― ― 
GMT 
(95% CI) 
MB 8.3 (5.2–13.2)  8.9 (7.9–10.0)  9.5 (8.1–11.2) 0.91a 0.90a 0.86a 
CB 6.3 (3.8–10.4)  7.7 (6.7–8.8)  9.5 (8.0–11.4) 0.66a 0.27a 0.36a 
p value (MB/CB) 0.36c 0.04c 0.78c ― ― ― 
Abbreviations: MB, maternal blood; HTG, high titer group; GMT, geometric mean titer, CB; cord blood; CI, confidence interval 
aKruskal–Wallis test, bchi-square test, cMann–Whitney test 
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Table 3. Comparison of Low Titer Group (NAT ≤ 1:16) with High Titer Group (NAT ≥ 1:32) 
Perinatal factor 
Maternal blood Cord blood 
LTG HTG p value LTG HTG p value 
Number 751 282  737 296  
Maternal age (years), median(IQR) 
31 
(28–35) 
28 
(25–31) 
<0.01 
31 
(28–35) 
28 
(25–31) 
<0.01 
GA(weeks-days), median(IQR) 
39-4 
(38-4–40-3) 
39-6 
(39-0–40-3) 
<0.01 
39-3 
(38-4–40-2) 
39-6 
(39-0–40-4) 
<0.01 
IgG (mg/dl), median (IQR) 
826 
(706–942) 
842 
(727–958) 
0.11 
1165 
(1005–1365) 
1268 
(1077–1440) 
<0.01 
Maternal smoking, n (%) 
138 
(18.5) 
55 
(19.6) 
0.67 
133 
(18.1) 
60 
(20.6) 
0.40 
Maternal obesity, n (%) 
75 
(10.3) 
28  
(10.2) 
0.96 
69 
(9.6) 
34 
(12.2) 
0.32 
PIH, n (%) 
30 
(4.0) 
3 
(1.1) 
0.02 
28 
(3.8) 
5 
(1.7) 
0.08 
Male, n (%) 
383 
(51.0) 
138 
(48.9) 
0.56 
374 
(50.8) 
147 
(49.7) 
0.75 
Number of siblings (No.), median (IQR) 
1 
(0–1) 
1 
(0–1) 
0.64 
1 
(0–1) 
1 
(0–1) 
0.71 
Abbreviations: LTG, low titer group (NAT ≤ 1:16); HTG, high titer group (NAT ≥ 1:32); IQR, interquartile range; GA, gestational age; PIH, 
pregnancy-induced hypertension. Note: Categorical variables were compared between the LTG and HTG using chi-square test. Continuous 
variables were compared using the Mann–Whitney test. 
 17 
 
Table 4. Results of Multivariate Logistic Regression Analysis Showing Associations between Perinatal Factors for High Neutralizing Antibody 
Titers. 
 
Perinatal factor 
Maternal blood Cord blood 
aOR 95% CI p value aOR 95% CI p value 
Maternal age 0.89 0.86–0.92 <0.01 0.90 0.87–0.93 <0.01 
GA 1.11 0.99–1.24 0.06 1.16 1.01–1.33 0.03 
IgG 1.00 1.00–1.01 0.01 1.00 1.00–1.01 0.02 
Maternal smoking  0.96 0.66–1.40 0.84 1.05 0.70–1.57 0.81 
Maternal obesity 1.02 0.63–1.66 0.92 1.23 0.73–2.05 0.44 
PIH 0.31 0.09–1.07 0.06 0.35 0.10–1.24 0.10 
Male  0.94 0.70–1.26 0.67 1.06 0.77–1.47 0.71 
Number of siblings 1.22 1.02–1.45 0.03 1.21 1.00–1.47 0.06 
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; GA, gestational age; PIH, pregnancy-induced hypertension. 
Note: Low titer group (NAT ≤ 1:16) was set as 0 and high titer group (NAT ≥ 1:32) was set as 1 for the objective 
variables were examined. 
